The Equisetum enzyme hetero-trans-β-glucanase (HTG) covalently grafts native plant cellulose (donor-substrate) to xyloglucan (acceptor-substrate), potentially offering a novel 'green' method of cellulose functionalisation. However, the range of cellulosic and non-cellulosic donor substrates that can be utilised by HTG is unknown, limiting our insight into its biotechnological potential. Here we show that HTG binds all celluloses tested (papers, tissues, hydrogels, bacterial cellulose) to radioactively- or fluorescently-labelled xyloglucan-heptasaccharide (XXXGol; acceptor-substrate). Glycol-chitin, glycol-chitosan and chitosan also acted as donor substrates but less effectively than cellulose. Cellulose-XXXGol conjugates were formed throughout the volume of a block of hydrogel, demonstrating penetration. Plant-derived celluloses (cellulose Iβ) became more effective donor-substrates after 'mercerisation' in ≥3 M NaOH; the opposite was true for bacterial cellulose Iα. Cellulose-XXXGol bonds resisted boiling 6 M NaOH, demonstrating strong glycosidic bonding. In conclusion, HTG stably grafts native and processed celluloses to xyloglucan-oligosaccharides, which may carry valuable 'cargoes', exemplified by sulphorhodamine. We thus demonstrate HTG's biotechnological potential to modify various cellulose-based substrates such as textiles, pulps, papers, packaging, sanitary products and hydrogels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2020.09.039 | DOI Listing |
J Funct Biomater
January 2025
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (ChiBioFarAm), University of Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.
Bone defects restoration has always been an arduous challenge in the orthopedic field due to the limitations of conventional grafts. Bone tissue engineering offers an alternative approach by using biomimetic materials, stem cells, and growth factors that are able to improve the regeneration of bone tissue. Different biomaterials have attracted great interest in BTE applications, including the poly(3-hexylthiofene) (P3HT) conductive polymer, whose primary advantage is its capability to provide a native extracellular matrix-like environment.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Department of Cardiothoracic Surgery, Weill Cornell Medicine, 525 E 68th St, New York, NY, 10065, USA.
Background: Baseline systemic inflammation is associated with worse long-term outcomes after coronary artery bypass grafting [CABG], but the mechanisms of this association are unclear. This study aims to explore the association between pre-operative white blood cell [WBC] count and CABG graft failure.
Methods: We pooled individual patient data from two randomized clinical trials with systematic CABG graft imaging.
J Plast Reconstr Aesthet Surg
November 2024
Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA. Electronic address:
Background: The long-term stability of allograft or native bone in facial vascularized composite allograft (fVCA) recipients is unclear. This study quantified long-term bone volume changes in facial transplants.
Methods: Computed tomography scans of eight fVCA recipients (2011-2023) were analyzed with Materialise Mimics.
Case Rep Nephrol Dial
December 2024
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
Introduction: A common complication of arteriovenous fistula (AVF) is thrombosis in the venous segment, which can impair vascular access unless a successful thrombectomy is performed.
Case Presentation: In this manuscript, we describe the case of a diabetic patient who had primary AVF in a snuff-box with subsequent superficialization of the medial vein of the forearm. Unfortunately, this section of the vein was occluded, although the fistula was patent through the cephalic vein (CV).
Artif Organs
January 2025
Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.
Intrahepatic islet transplantation is a promising strategy for β-cell replacement therapy in the treatment of Type 1 Diabetes. However, several obstacles hinder the long-term efficacy of this therapy. A major challenge is the scarcity of donor organs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!